CDK2 and glioblastoma: The quinazolinone 5c triggered cell cycle arrest in the S phase in melanoma MDA-MB-435 cells and in the G2/M phase in glioblastoma SNB-75 cells suggesting that CDK2 could be the potential biological target for the newly synthesised congeners.